Astria Therapeutics initiated with an Outperform at JMP Securities
JMP Securities analyst Jonathan Wolleben initiated coverage of Astria Therapeutics (ATXS) with an Outperform rating and $26 price target ...
Buy Rating for Astria Therapeutics: Promising Prospects in HAE and Atopic Dermatitis Markets
Jonathan Wolleben, an analyst from JMP Securities, has initiated a new Buy rating on Astria Therapeutics (ATXS).Invest with Confidence: Follow ...
JMP Securities starts Astria Therapeutics stock at Market Outperform
JMP Securities initiated coverage on Astria Therapeutics (NASDAQ: ATXS), assigning a Market Outperform rating and setting a ...
JMP Securities starts Astria Therapeutics stock with $26 target
Astria Therapeutics' focus on leveraging its half-life extension technology to create long-acting mAbs targeting derisked targets in established markets has positioned the company favorably in the ...
ETF Daily News6d
Astria Therapeutics’ (ATXS) “Buy” Rating Reiterated at HC Wainwright
HC Wainwright reiterated their buy rating on shares of Astria Therapeutics (NASDAQ:ATXS – Free Report) in a research report released on Thursday,Benzinga reports. HC Wainwright currently has a $ ...
news.stocktradersdaily1d
(ATXS) Trading Signals
Longer Term Trading Plans for ATXS. Buy ATXS near 7.19 target 9.02 stop loss @ 7.17 Details; The technical summary data tells us to buy ATXS near 7.19 with an upside target of 9.0 ...
Investing2d
Astria Therapeutics Inc (ATXS)
Astria Therapeutics recently reported its third-quarter financial results and provided a corporate update, highlighting its promising Phase 1a data for STAR-0215, a potential ...